The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. [electronic resource]
Producer: 20100816Description: 298 p. digitalISSN:- 1471-2407
- Adolescent
- Adult
- Alkaline Phosphatase -- metabolism
- Ascorbic Acid -- pharmacology
- Bone Marrow Cells -- drug effects
- Calcification, Physiologic -- drug effects
- Cell Differentiation -- drug effects
- Cell Proliferation -- drug effects
- Cell Separation
- Cells, Cultured
- Child
- Child, Preschool
- Dasatinib
- Dexamethasone -- pharmacology
- Dose-Response Relationship, Drug
- Extracellular Matrix -- drug effects
- Gene Expression Regulation -- drug effects
- Glycerophosphates -- pharmacology
- Humans
- Integrin-Binding Sialoprotein
- Kinetics
- Mesenchymal Stem Cells -- drug effects
- Middle Aged
- Osteoblasts -- drug effects
- Osteogenesis -- drug effects
- Osteopontin -- metabolism
- Phosphorylation
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Mas
- Pyrimidines -- pharmacology
- RANK Ligand -- metabolism
- Sialoglycoproteins -- metabolism
- Thiazoles -- pharmacology
- Young Adult
- src-Family Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.